GSK Stock Analysis: Buy, Sell, or Hold?
GSK - GSK plc American Depositary Shares (Each representing two Ordinary Shares)
$48.70
-0.43 (-0.88%)
âŧ
5d:
-4.4%
30d:
+4.62%
90d:
-5.36%
WAIT
LOW Confidence
Analysis Updated: Nov 3, 2026 12:00 AM ET
Earnings: Oct 28, 2026
0d
Get Alerted When GSK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: GSK is fairly priced but lacks strong directional signals. At -1.5% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: GSK is fairly priced but lacks strong directional signals. At -1.5% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$62.28
Based on 4.1% avg growth
INTRINSIC VALUE TODAY
$38.67
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GSK is currently trading at $48.70, which is considered fair relative to its 30-day fair value range of $47.11 to $50.20. The stock's valuation (Forward PE: 9.8) is in line with its historical norms (10.3). Remarkably, the market is currently pricing in an annual earnings decline of 1.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, GSK is in a strong downtrend. The price is currently testing key support at $47.35. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 49/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $59.12 (+21.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GSK is in a strong downtrend. The price is currently testing key support at $47.35. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 49/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $59.12 (+21.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$47.11 -
$50.20
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (49/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 21.4% below Wall St target ($59.12)
- WARNING: Composite score 47/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$47.11 -
$50.20
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$47.36
Resistance Level
$51.44
Current Trend
Strong Downtrend
Technical data as of
Nov 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.82
Wall Street Target
$59.12
(+21.4%)
Revenue Growth (YoY)
4.0%
Earnings Growth (YoY)
-22.8%
Profit Margin
13.0%
Valuation Discount vs History
-1.5% cheaper
PE vs Historical
9.8 vs 10.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.5%
(market-implied from PE analysis)
1-Year Target
$47.97
(-2%)
2-Year Target
$47.25
(-3%)
3-Year Target
$46.54
(-4%)
3-Yr Target (if PE normalizes)
(PE: 10â10)
$48.80
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 4.1%)
$111.19
(+128%)
Base:
(SPY PE: 9.8, Growth: 4.1%)
$54.99
(+13%)
Bear:
(PE: 8.3, Growth: 4.1%)
$46.74
(-4%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (17x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 17.12 | Current EPS (TTM): $2.87
Bull Case
$93.36
(+92%)
Analyst growth 72.8%, PE expands to 18.8
Base Case
$84.87
(+74%)
Market implied 72.8%, PE stable at 17.1
Bear Case
$33.41
(-31%)
Severe decline -20.0%, PE contracts to 14.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.8 to 10.3
Stabilization Target:
$51.07
(+4.9%)
PE Expansion Potential:
+4.9%
Share & Embed Analysis
Last updated: November 03, 2026 10:45 PM ET
Data refreshes hourly during market hours. Next update: 11:45 PM
Data refreshes hourly during market hours. Next update: 11:45 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GSK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ABBV
AbbVie Inc |
STRONG BUY
29 analysts |
$283 | 50 HOLD |
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1404 | 29 SELL |
|
GILD
Gilead Sciences Inc |
STRONG BUY
28 analysts |
$171 | 42 HOLD |
|
MRK
Merck & Company Inc |
BUY
28 analysts |
$160 | 49 HOLD |
|
BIIB
Biogen Inc |
BUY
36 analysts |
$264 | 38 SELL |
